ArticleFrontiers in oncology2026
Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This case report aims to enhance awareness and understanding of intracranial mesenchymal tumors with FET::CREB fusion by illustrating the associated diagnostic challenges, thereby contributing to the limited literature on this rare entity. Methods: This report presents a case of a 58-year-old female who presented with a persistent headache. Neuroimaging revealed a well-defined cystic mass in the right temporoparietal lobe. The patient underwent gross total resection (GTR). Results: Histopathological analysis was consistent with an intracranial mesenchymal tumor, showing immunopositivity for Desmin, MUC4, CD99, and ALK. Next-generation sequencing identified an EWSR1::ATF1 gene fusion, confirming the diagnosis of an intracranial mesenchymal tumor, FET::CREB fusion-positive. Approximately two years postoperatively, follow-up imaging revealed local tumor recurrence, which was managed with a second GTR. Conclusion: This case highlights the diagnostic challenges, potential for recurrence, and importance of molecular profiling in the accurate diagnosis of this rare tumor entity. GTR remains the primary treatment, though the long-term biological behavior and optimal management strategies require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.